We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan Laboratories lost its bid to launch generic Topamax capsules and tablets after a federal court barred the company from selling its version of the epilepsy treatment prior to late 2008.